Published: Jan 26, 2021
NEW YORK, Jan. 26, 2021 /PRNewswire/ Q Biomed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat HCC.